COLL 108 |
| Nanomedicine encompasses a vast area of biomedical research, from the development of new generation of contrast agents for diagnostic imaging to synthesizing targeted delivery vehicles of therapeutic drugs as well as synthetic, non-viral vectors for gene therapy. In our institute we are actively pursuing various medicinal avenues by developing novel hybrid nanoplatforms like the ‘nanoclinic', which can provide combined diagnosis and therapy of tumor cells in a target-specific manner. The organically modified silica (ORMOSIL) nanoparticles developed here have been used as a new-generation drug carrier for photodynamic therapy (PDT) of cancer, as well as an efficient non-viral gene carrier, capable of transfecting neuronal cells in vivo with superior efficacy over viral vectors. We are also fabricating ‘multimodal' nanocomposites with combined optical, magnetic, plasmonic and PET imaging probes as well as chemotherapeutic drugs with the goal of early diagnosis and therapy of diseases and real-time monitoring of drug action. |
|
Advances in Nanomedicine
2:00 PM-5:30 PM, Sunday, 10 September 2006 Sir Francis Drake -- Monterey/Cypress Rooms, Oral
Division of Colloid & Surface Chemistry |